EUVIMEDEUVIMED entdecken
Crossref

Gustave Roussy Immune Score in Nivolumab Treated Metastatic Renal Cell Carcinoma

Pınar Kubilay Tolunay, Bediz Kurt İnci, Büşra Akay Hacan, Serkan Yaşar, Cengiz Karaçin, Öztürk Ateş

Medical Records · 09.09.2025 · 7 (3) · 679-82

DOI: 10.37990/medr.1706352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Records, online erschienen am 09.09.2025. Verfasst von Pınar Kubilay Tolunay und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The aim of this study is to evaluate the Gustave Roussy immune (GRIm) score as a biomarker for survival in metastatic renal cell carcinoma (mRCC) patients receiving nivolumab following first-line treatment. Material and Method: 41 mRCC patients who were given nivolumab beyond first line were included in this retrospective study. Data on ratio of neutrophile to lymphocyte, albumin, and LDH levels were utilized to determine GRIm score. Patients scoring 2–3 were grouped into the high GRIm score, whereas those scoring 0–1 were grouped as the low GRIm score. The association between the GRIm score and progression-free survival (PFS) with overall survival (OS) was examined.

Results

Thirty patients exhibited a low GRIm score, whereas eleven presented a high GRIm score. Prolonged median PFS and OS, with values of 7.06 months compared to 2.89 months (p=0.002) and 20.34 months compared to 4.27 months (p<0.001), are found respectively in low GRIm score group. In terms of PFS, a higher GRIm score was identified as an independent prognostic indicator but lacked prognostic significance for OS in multivariable analysis.

Conclusion

The GRIm score may be used as an accessable and cost-effective prognostic biomarker in mRCC patients receiving nivolumab, and may assist clinicians in patient selection, thus improving therapeutic efficacy and the efficient use of clinical resources.

Zitieren

APA

Tolunay, P. K., İnci, B. K., Hacan, B. A., Yaşar, S., Karaçin, C., & Ateş, Ö. (2025). Gustave Roussy Immune Score in Nivolumab Treated Metastatic Renal Cell Carcinoma. Medical Records, 7(3), 679-82. https://doi.org/10.37990/medr.1706352

Vancouver

Tolunay PK, İnci BK, Hacan BA, Yaşar S, Karaçin C, Ateş Ö. Gustave Roussy Immune Score in Nivolumab Treated Metastatic Renal Cell Carcinoma. Medical Records. 2025;7(3):679-82. doi:10.37990/medr.1706352

BibTeX
@article{Tolunay2025,
  author = {Tolunay, Pınar Kubilay and İnci, Bediz Kurt and Hacan, Büşra Akay and Yaşar, Serkan and Karaçin, Cengiz and Ateş, Öztürk},
  title = {Gustave Roussy Immune Score in Nivolumab Treated Metastatic Renal Cell Carcinoma},
  journal = {Medical Records},
  year = {2025},
  volume = {7},
  number = {3},
  pages = {679--82},
  doi = {10.37990/medr.1706352}
}
Kostenlos starten →